Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity

Clinical Orthopaedics and Related Research

Volumn 438, Issue , 2005, Pages 128-136

  Wilkins, R M ^a,b   Cullen, J W ^a   Camozzi, Anne B ^a,b   Jamroz, B A ^a   Odom, L ^b  

^a PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; ANTINEOPLASTIC AGENT;

ADULT; ARTERIOGRAPHY; BACTEREMIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYOSITIS; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN INFLAMMATION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VASCULARIZATION; VALIDATION PROCESS; ADOLESCENT; ARTICLE; BONE TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMB; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PREOPERATIVE CARE; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; EXTREMITIES; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MALE; OSTEOSARCOMA; PREOPERATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 24344491039     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000179736.10871.76     Document Type: Conference Paper

References (29)

1. Bacci G, Ferrari S, Bertoni F, et al: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18:4016-4027, 2000.
2. Bacci G, Ferrari S, Longhi A, et al: Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother 13:93-99, 2001.
3. Bacci G, Ferrari S, Mercuri M, et al: Neoadjuvant chemotherapy for extremity osteosarcoma: Preliminary results of the Rizzoli's 4th study. Acta Oncol 37:41-48, 1998.
4. Bacci G, Ferrari S, Mercuri M, et al: Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for a minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 69:230-236, 1998.
5. Bacci G, Ferrari S, Tienghi A, et al: A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol 27:98-104, 2001.
6. Benjamin RS, Chawla SP, Carrasco CH, et al: Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intraarterial cisplatinum. Ann Oncol 3:3-6, 1992.
7. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002.
8. Brosjo O: Surgical procedure and local recurrence in 224 patients treated 1982-1997 according to two osteosarcoma chemotherapy protocols: The Scandinavian Sarcoma Group experience. Acta Orthop Scand 285(Suppl):58-61, 1999.
9. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, v3.0. (CTCAE). Division Cancer Therapy and Diagnosis, National Cancer Institute, National Institutes of Health, Dept. Health Human Services, Rockville MD, December 12, 2003.
10. Cancer Therapy Evaluation Program: Common Toxicity Criteria, v3.0, (CTC). Division Cancer Therapy and Diagnosis, National Cancer Institute, National Institutes of Health, Dept. Health Human Services, Rockville MD, March 23, 1998.
11. Carrasco CH, Charnsangavej C, Raymond AK, et al: Osteosarcoma: Angiographic assessment of response to preoperative chemotherapy. Radiology 170:839-842, 1989.
12. Davis AM, Bell RS, Goodwin PJ: Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 12:424-431, 1994.
13. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard D: A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res 286:241-246, 1993.
14. Ferrari S, Bacci G, Picci P, et al: Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8:765-771, 1997.
15. Ferrari S, Mercuri M, Picci P, et al: Nonmetastatic osteosarcoma of the extremity: Results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intra-arterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumor 85:458-464, 1999.
16. Friedman MA, Carter SK: The therapy of osteogenic sarcoma: Current status and thoughts for the future. J Surg Oncol 4:82-89, 1972.
17. Fuchs N, Bielack SS, Epler D, et al: Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893-899, 1998.
18. Goorin AM, Schwartzentruber DJ, Devidas M, et al: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-1580, 2003.
19. Huvos AG, Rosen G, Marcove RC: Primary osteogenic sarcoma: Pathologic aspects in 10 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101:14-18, 1977.
20. Jaffe N, Knapp J, Chuang V, et al: Osteosarcoma. Intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum II (CDP); angiographic, pathologic, and pharmacologic studies. Cancer 51:402-407, 1983.
21. Jaffe N, Raymond K, Ayala A, et al: Effect of cumulative courses of intra-arterial cis-di-amminedichloroplatinum II on the primary tumor in osteosarcoma. Cancer 63:63-67, 1989.
22. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group, J Clin Oncol 15:76-84, 1997.
23. Quintana J, Beresi V, DelPozo H, et al: Intra-arterial cisplatin given prior to surgery in osteosarcoma: Grade of necrosis and size of tumor as major prognostic factors. Am J Pediatr Hematol Oncol 13:269-273, 1991.
24. Rha SY, Chung HC, Gong SJ, et al: Combined preoperative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Oncol Rep 6:631-637, 1999.
25. Stewart DJ, Benjamin RS, Zimmerman S, et al: Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res 43:917-920, 1983.
26. Uchida A, Myoui A, Araki N, et al: Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 79:411-415, 1997.
27. Wilkins RM, Cullen JW, Odom L, et al: Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 10:498-507, 2003.
28. Wilkins RM, Soubeiran A: The Phenix expandable prosthesis: Early American experience. Clin Orthop Relat Res 382:51-58, 2001.
29. Winkler K, Bielack S, Delling G, et al: Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 66:1703-1710, 1990.